Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
https://www.glpg.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,123
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Galapagos NV’s ISS governance QualityScore as of 1 June 2024 is 7. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 4; Compensation: 10.